June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Long term follow up of Sorsby fundus dystrophy patients treated with intravitreal bevacizumab
Author Affiliations & Notes
  • Hussein Almuhtaseb
    Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
  • Suman Pilli
    Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
  • Andrew J Lotery
    Eye Unit, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
    Faculty of Medicine, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Footnotes
    Commercial Relationships Hussein Almuhtaseb, None; Suman Pilli, None; Andrew Lotery, Roche: Sub-investigator IVAN study (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 3839. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hussein Almuhtaseb, Suman Pilli, Andrew J Lotery; Long term follow up of Sorsby fundus dystrophy patients treated with intravitreal bevacizumab. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):3839. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

Tissue inhibitor of metalloproteinases-3 (TIMP3) is mutated in Sorsby fundus dystrophy (SFD). In this AD disease central vision loss is due to choroidal neovascularization (CNV). The purpose of this study is to report the long term results of treatment with intravitreal bevacizumab (IVB).

 
Methods
 

Retrospective case note review of 7 eyes of 4 patients with CNV secondary to SFD treated with IVB injections (0.05 mL, 1.25 mg) performed. In one eye, 1 session of PDT was carried out before. Best-corrected visual acuity (BCVA) ETDRS L charts, optical coherence tomography (OCT), and/or fluorescein angiography (FFA) before and after treatment were assessed. Number of visits post-1st CNV activity, number of injections, and number of recurrences were recorded. Recurrence of CNV activity was defined as the presence of active CNV based on OCT, FFA or subjective change in symptoms after a minimum of 2 follow-up visits with no evidence of CNV after a previous IVB.

 
Results
 

All patients had a family history of SFD. DNA analysis confirmed mutation c.610A>T (p.Ser204Cys) in exon 5 of TIMP3 gene in all patients. All patients were female, age ranged from (39-48) years (mean: 44 years). The follow-up period ranged from 11 to 95 months (median: 23 months). BCVA ranged from 35 to 83 L (median: 57 L) at the time of the 1st CNV activity. The number of visits post-1st CNV activity ranged from (5-68) visits (median: 29 visits), number of IVB ranged from (1-55) IVB (median: 7 IVB), and number of recurrences ranged from (0-13 recurrences) (median: 4 recurrences). At their respective last follow-up visit, BCVA ranged from (25-80) L (median: 63 L) . In 3 eyes BVCA improved by a range of (+1-+39) L, with a Mean Change from Baseline in BCVA of +16.7 L. In 4 eyes visual acuity declined by a range of (-4 to -32) L, with a Mean Change from Baseline in BCVA of -17.5 L. The main macular OCT finding that characterised BCVA decline despite treatment was atrophic changes, fibrosis or a combination of both.

 
Conclusions
 

Intravitreal bevacizumab ameliorates the rapid vision loss seen in SFD patients affected by CNV. This effect is sustained for up to 95 months but careful follow up is necessary to promptly treat recurrent CNV. Macular scarring can progress despite treatment but the area of scar tissue appears less with bevacizumab treatment of natural history.  

 
CF and OCT of a 47-y-old before (A,B) and after (C,D) 21 IVB injections.
 
CF and OCT of a 47-y-old before (A,B) and after (C,D) 21 IVB injections.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×